Baylor Scott & White Medical Center - Temple

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Prostate cancer4 trials
• Bladder cancer2 trials
• Multiple myeloma2 trials
• Aortic stenosis1 trial
• Colorectal cancer1 trial
• Heart failure1 trial
• Lung cancer1 trial
• Mild cognitive impairment1 trial
• Peripheral artery disease1 trial
• Sickle cell disease1 trial
• Thalassaemia1 trial

Phase

• Phase 36 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Active, not recruiting7 trials
• Completed3 trials
• Recruiting3 trials
• Not yet recruiting2 trials

Lead sponsor

• Pfizer4 trials
• Baylor Research Institute3 trials
• Eli Lilly and Company2 trials
• Abiomed Inc.1 trial
• Bayer1 trial
• and 4 more

Running trials

• Recruiting

  Intravascular Ultrasound Imaging Guidance for Optimal Revascularization of Limb Arteries

  NCT07353905· Baylor Research Institute· Source

  Contact: Margarite Grable

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Trauma BPE Prolonged Exposure Therapy for Injured Individuals Admitted to a Level I Trauma Center

  NCT06210711· Baylor Research Institute· Source

  Contact: Valerie Danesh, PhD

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Recruiting

  A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Pfizer· Source

• Active, not recruiting

  Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

  NCT04452591· Phase 3· CG Oncology, Inc.· Source

• Active, not recruiting

  A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

  NCT04122976· Bayer· Source

• Active, not recruiting

  An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

  NCT04053803· Phase 2· Imara, Inc.· Source

• Active, not recruiting

  A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

  NCT03706365· Phase 2/3· Eli Lilly and Company· Source

• Active, not recruiting

  Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  NCT03395197· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• Multiple myeloma1 recruiting
• Peripheral artery disease1 recruiting

Closed trials

• Completed

  Prospective Evaluation of Neurocognition in Patients Undergoing Transcatheter Aortic Valve Replacement

  NCT05614986· Baylor Research Institute· Source

• Completed

  To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

  NCT04894591· Jazz Pharmaceuticals· Source

• Completed

  SVC Occlusion in Subjects With Acute Decompensated Heart Failure

  NCT03836079· Abiomed Inc.· Source